Ainsworth CM, Vickers AD, Le Moine J. Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A767. doi: 10.1016/j.jval.2017.08.2189
Grimes R, Grant L, Kaur S, Spencer H, Brookes B, Bennett B. Evaluating patient reported outcomes commonly used in current lung cancer clinical trials. Value Health. 2017 Oct 1;20(9):PA764.
Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19 guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and one year outcomes following percutaneous coronary intervention. Presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct 1; 20(9):A405. doi: 10.1016/j.jval.2017.08.041
Sluga-O'Callaghan M, Ansquer V, Frugier G, Mai C. Regulatory requirements for non-interventional studies collecting patient preferences and experiences in France, Germany and the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A707.
Bonner N, Hall R, Tritton T, Grimes R, Trennery C, Spencer H, Bennett B. Rare diseases, are caregivers just as affected as patients? Value Health. 2017 Oct 1;20(9):PA562.
Spencer H, Grant L, Kaur S, Grimes R, Brookes B, Bennett B. Special considerations for conducting qualitative interviews with cancer patients and their caregivers for the purpose of developing clinical outcome assessments. Poster presented at the 2017 ISPOR 20th Annual European Conference; November 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A777. doi: 10.1016/j.jval.2017.08.2247
Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, Lee CR, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May 1; 20(5):A276.
Talbird SE, La EM, Mauskopf J, Krueger WS, Altland A, Daniels VJ, Pillsbury M, Wolfson LJ. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A325.
Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.
Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.
Kurosky S, Lorenzo M, Cuyun Carter G, Parikh RC, Winfree K, Kaye JA. Health care resource utilization and costs of metastatic non-small cell lung cancer in select European countries. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A361.
Svedsater H, Doward L, Whalley D, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N. Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD): follow-up interviews on patient-centered outcomes. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A205.
Ajmera MR, Goyal RK, Davis KL. Incremental economic burden of cardiometabolic disorders among patients with epilepsy. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A191.
Graham CN, Mcbride D, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, Augustin M. Cost-effectiveness of secukinumab in moderate to severe psoriasis compared with other biologics in Germany. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A157.
Augustin M, Graham CN, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, Mcbride D. A cost-per-responder analysis of secukinumab compared with ustekinumab through 52 weeks in Germany: results from the clear study of patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A158.
Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. Analysis of humanistic burden reveals a need for opioid use disorder (OUD) disease-specific HRQoL instruments. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A300.
Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. The economic burden of opioid use disorder (OUD): results of a structured literature review. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A298.
Sluga-O'Callaghan M, Derrien Ansquer V, Mai C. Evolution of regulatory requirements for retrospective observational studies using medical records in France, Germany, Spain and the UK. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(2017):A68.
McLeod L, Sikirica MV, Qin S, Joshi AV, Sweeney CT, Blum SI. Psychometric evaluation of the nausea and vomiting questionnaire in patients with type 2 diabetes mellitus receiving a glucagon-like peptide-1 receptor agonist. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A175.
McLeod L, Sikirica MV, Davenport E, Sweeney CT, Joshi AV. The impact of GLP-1 induced nausea and vomiting on work productivity and health-related quality of life in patients with T2DM. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A172.
Bell K, Meyers J, Candrilli SD, Ajmera MR. Characteristics and costs of patients with type 2 diabetes augmenting metformin with dapagliflozin versus glipizide: an analysis of commercial claims data. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A169.
Herring W, Carrico J, Mladsi D, Pierson RF, Lofland JH. A review of vision-related utility values and their suitability for use in cost-effectiveness models in age-related macular degeneration. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A159.
Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.
DeMuro C, Gnanasakthy A, Price M, Winnette R, Desphande A. Development of a daily diary to assess signs and symptoms of genital herpes. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A80.
Mansfield CA, Boeri M, Reyes C, Masaquel AS, Sutphin JN, Li J. How can we assess the impact of cost on patient treatment preferences in CLL treatment? Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A118.
Sherif B, Graham CN, Neidhardt K, Gilloteau I, O'Neill CB, Mcbride D, Augustin M. EQ-5D-3L utilities tariffs: differences in German and UK utilities and QALYS in patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A331.
Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.
Goyal RK, Ajmera MR, Davis KL. Recent trends in emergency department visits resulting from unintentional overdose of non-opioid analgesics, antipyretics, and antirheumatics in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A231.
Nagar SP, Sato M, Montgomery W, Nakamura T, Imagawa H, Davis KL. Treatment patterns and characteristics of adult patients with attention deficit/hyperactivity disorder receiving atomoxetine in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A305.
Nagar SP, Fox KM, Rane PP, Beaubrun A, Qian Y, Inomata H, Davis KL, Meyers J, Kajinami K. Incidence of cardiovascular events among secondary prevention patients treated with statins or ezetimibe in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A261.
Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.
Johnson KD, Jiang Y, Weiss T, Graham J. Herpes zoster vaccine effectiveness and waning of effectiveness. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A326.
Park J, Covert D, Fairchild C, Brubaker M, Martin SA, Lewis S, DeMuro C. Development of an eye drop comfort measure for topical ocular drop application. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A364.
Azzabi Zouraq I, Wilson M, Heather G, Curtis R, Luo M, Khalid JM, Minda K. Cost-effectiveness of vedolizumab compared with ustekinumab as treatment for patients with moderately to severely active Crohn´s disease in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A183.
Dave I, Nagar SP, Arif AA, Laditka SB, Huber LR. Association between prescription-taking status and total direct health care cost among patients with asthma. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A357.
Puig L, Griffiths CE, Zhou Y, Gilloteau I, Guana A, Houghton K, Stull DE. Differential effects of secukinumab vs. ustekinumab for treatment of moderate to severe psoriasis on work productivity and activity impairment: a structural equation modelling approach using the CLEAR 52-week study. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A161.
Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health. 2017 Apr;20(4):618-26.
Layton JB, Kim Y, Alexander GC, Emery SL. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA. 2017 Mar 21;317(11):1159-66. doi: 10.1001/jama.2016.21041
Wolowacz S. Editorial: ISPOR good research practices task force report—mapping to estimate utility values from non–preference-based outcome measures. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026
Wolowacz S. New ISPOR recommendations - mapping methods for estimation of health state utility. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026
Gnanasakthy A, Mordin M, Evans E, Doward L, DeMuro C. A review of patient-reported outcome labeling in the United States (2011-2015). Value Health. 2017;20(3):420-9. doi: 10.1016/j.jval.2016.10.006
Jick H, Hannan MT, Stergachis A, Heidrich F, Perera DR, Rothman KJ. Vaginal spermicides and gonorrhea. JAMA. 1982 Jan 1;248(13):1619-21.
Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA. 1978 Dec 1;240(23):2548-52.
Jick H, Dinan B, Rothman KJ. Non-contraceptive estrogens and nonfatal myocardial infarction. JAMA. 1978 Apr 3;239(14):1407-8. doi: 10.1001/jama.1978.03280410049017
Jick H, Dinan B, Rothman KJ. Oral contraceptives and nonfatal myocardial infarction. JAMA. 1978 Apr 3;239(14):1403-6.